These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 19895224)

  • 1. Ex vivo biomarkers: functional tools to guide targeted drug development and therapy.
    Clark DP
    Expert Rev Mol Diagn; 2009 Nov; 9(8):787-94. PubMed ID: 19895224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer proteomics: from biomarker discovery to signal pathway profiling.
    Bichsel VE; Liotta LA; Petricoin EF
    Cancer J; 2001; 7(1):69-78. PubMed ID: 11269650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamic biomarkers for molecular cancer therapeutics.
    Sarker D; Workman P
    Adv Cancer Res; 2007; 96():213-68. PubMed ID: 17161682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Hematologic malignancies /pediatric malignancies-current status of molecular target therapy for hematologic cancer].
    Usui N
    Gan To Kagaku Ryoho; 2010 May; 37(5):805. PubMed ID: 20524247
    [No Abstract]   [Full Text] [Related]  

  • 5. Using biomarkers in drug development.
    Workman P
    Clin Adv Hematol Oncol; 2006 Oct; 4(10):736-9. PubMed ID: 17099630
    [No Abstract]   [Full Text] [Related]  

  • 6. Modulation of cellular signaling pathways: prospects for targeted therapy in hematological malignancies.
    Ravandi F; Talpaz M; Estrov Z
    Clin Cancer Res; 2003 Feb; 9(2):535-50. PubMed ID: 12576416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Molecular targeted therapy for cancer].
    Sone S; Kuramoto T; Sato S; Mitsuhashi A; Kakiuchi S; Goto H; Tada H; Nishioka Y
    Nihon Rinsho; 2010 Jun; 68(6):997-1006. PubMed ID: 20535947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamic biomarkers in early oncology drug development.
    Takimoto CH
    Eur J Cancer; 2009 Sep; 45 Suppl 1():436-8. PubMed ID: 19775662
    [No Abstract]   [Full Text] [Related]  

  • 9. Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers.
    Lee JW; Figeys D; Vasilescu J
    Adv Cancer Res; 2007; 96():269-98. PubMed ID: 17161683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New science-based endpoints to accelerate oncology drug development.
    Kelloff GJ; Sigman CC
    Eur J Cancer; 2005 Mar; 41(4):491-501. PubMed ID: 15737552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer proteomics and its application to discovery of therapy response markers in human cancer.
    Smith L; Lind MJ; Welham KJ; Cawkwell L;
    Cancer; 2006 Jul; 107(2):232-41. PubMed ID: 16752413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents.
    Le Tourneau C; Vidal L; Siu LL
    Drug Resist Updat; 2008 Jun; 11(3):99-109. PubMed ID: 18515176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of ex vivo systems for biomarker discovery.
    Lavallie ER; Dorner AJ; Burczynski ME
    Curr Opin Pharmacol; 2008 Oct; 8(5):647-53. PubMed ID: 18771752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical proteomics: from biomarker discovery and cell signaling profiles to individualized personal therapy.
    Calvo KR; Liotta LA; Petricoin EF
    Biosci Rep; 2005; 25(1-2):107-25. PubMed ID: 16222423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug resistance in cancer - searching for mechanisms, markers and therapeutic agents.
    O'Connor R; Clynes M; Dowling P; O'Donovan N; O'Driscoll L
    Expert Opin Drug Metab Toxicol; 2007 Dec; 3(6):805-17. PubMed ID: 18028026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteomics and the haematologist.
    Rees-Unwin KS; Morgan GJ; Davies FE
    Clin Lab Haematol; 2004 Apr; 26(2):77-86. PubMed ID: 15053800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-associated antigens and biomarkers in cancer and immune therapy.
    Malyankar UM
    Int Rev Immunol; 2007; 26(3-4):223-47. PubMed ID: 17558745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cancer biomarker problem.
    Sawyers CL
    Nature; 2008 Apr; 452(7187):548-52. PubMed ID: 18385728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating drug efficacy and toxicology in three dimensions: using synthetic extracellular matrices in drug discovery.
    Prestwich GD
    Acc Chem Res; 2008 Jan; 41(1):139-48. PubMed ID: 17655274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in clinical oncoproteomics.
    Jain KK
    J BUON; 2007 Sep; 12 Suppl 1():S31-8. PubMed ID: 17935275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.